Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06503510 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of Interleukin-13 Pathways on Pain and Itch Sensitivity

Study acronym: IL-13
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 4, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Recruiting
    • Secondary endpoints: details revised at 5 of 8 entries
    • Site details revised at 3 of 3 sites
    v5
  2. Start date: Nov 13, 2024 to Jan 6, 2025v4
  3. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 1 to 3
    • Start date changed from estimate of Oct 1, 2024 to Nov 13, 2024
    v3
  4. Study title shortened, about 10 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Trial Details
NCT Number NCT06503510
Lead Sponsor Aalborg University
Conditions
(from sponsor)		 Itch
Related terms Pruritus
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov